drugset / Trial / NCT02944435

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

NCT02944435

Phase 1 Completed 14 enrolled Calithera Biosciences, Inc
RandomizedCrossoverOpen-labelTreatment

Summary

This is a Phase 1, randomized, single-dose, 2-way crossover PK comparability study of CB-839 administered as capsule and tablet formulations in healthy adult subjects.

Timeline

Start
2016-10
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject CB-839 Unknown 600 mg Oral

Indications

No indication recorded.